Divestiture

A new survey shows nearly half of employers are considering international drug sourcing, a legally murky strategy, as cost control dethrones talent retention.

A new program helps heritage brands discreetly adopt AI, enhancing exclusivity and operations behind the scenes without compromising their coveted identity.

A jury found Live Nation runs an illegal monopoly, but the company vows to fight the verdict. The ruling could reshape the live entertainment landscape.

Wisconsin's top court affirms Pabst's liability for a contractor's fatal asbestos exposure, setting a major precedent for corporate accountability.

A St. Louis contractor was forced to pay $200,000 in back wages after an investigation found workers were underpaid on a public project.

Investors eye BioCryst's May 6th report for insights into ORLADEYO's growth, a pivotal acquisition, and its strategy in the competitive rare disease market.

Lobbying spending shattered records at $5.3 billion in 2025, driven by battles over trade, taxes, AI, and a surge in Trump-aligned influence firms.

A proposed $108.5M FDA funding boost aims to modernize infant formula rules, paving the way for plant-based options and a more secure supply chain.

ASIC reports a smaller loss but slumping revenue as it sells key NYC properties. With low cash and NYSE warnings, is this a survival plan or a fire sale?

On a day celebrating his legacy, Bruno Mars donated $1 million to a future Nevada children's hospital, spotlighting a critical healthcare crisis.

After three decades of talks, legislation for the K'ómoks First Nation's modern treaty promises self-governance but faces opposition from neighbours.

A federal judge has denied Binance and its ex-CEO's attempt to force arbitration, allowing a billion-dollar securities class action to proceed in court.

The Alaska Native corporation's spring distribution highlights a unique model where financial success directly fuels cultural vitality and environmental restoration.

Stepping into the role of Chairman and CEO, Dianne Taube ushers in a new era for the influential foundation with a focus on innovation and measurable impact.

A major US mutual life insurer is launching a Bermuda reinsurer with Agam Capital's help, highlighting a trend of using tech to optimize capital offshore.

GoldenTree's oversubscribed $3B fund close highlights a major shift as institutional investors seek flexible, high-yield private credit strategies.

With promising Phase 2 data for its novel peptide therapies, Sapience Therapeutics is engaging investors, signaling a critical push for future growth.

Italian infrastructure giant Mundys can now own nearly 30% of Getlink, a key move in European transport that passed the UK's strict security review.

A jury found Abbott's Similac caused a fatal gut disease in premature infants, igniting a legal firestorm over what the formula giant knew and when.

A Chicago jury found Abbott liable for infants' injuries from Similac, adding to a wave of lawsuits over the deadly intestinal disease NEC.